(S (NP (NNP Hepatitis) (NNP C) (NN virus) (PRN (-LRB- -LRB-) (NP (NNP HCV)) (-RRB- -RRB-)) (NN infection)) (VP (VBZ is) (ADJP (JJ endemic)) (PP (IN in) (NP (NP (NP (NNS people)) (SBAR (WHNP (WP who)) (S (VP (VBP inject) (NP (NNS drugs)))))) (PRN (-LRB- -LRB-) (NP (NNP PWID)) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (NN prevalence) (NNS estimates)) (PP (IN above) (NP (CD 60) (NN percent))) (PP (IN for) (NP (NP (NNP PWID)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))))) (. .))
(S (S (NP (JJ Previous) (VBG modeling) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ direct) (VBG acting) (JJ antiviral) (PRN (-LRB- -LRB-) (NNP DAA) (-RRB- -RRB-)) (NN treatment)) (VP (MD can) (VP (VB lower) (NP (NP (JJ overall) (NN prevalence)) (PP (IN in) (NP (DT this) (NN population)))))))))) (, ,) (CC but) (S (NP (NN treatment)) (VP (VBZ is) (ADVP (RB often)) (VP (VBN delayed) (PP (IN until) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ advanced) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ fibrosis)) (NP (NN stage) (CD 3))) (CC or) (ADVP (RB later))) (-RRB- -RRB-)))))) (PP (JJ due) (PP (TO to) (NP (NN cost))))))) (. .))
(S (NP (NP (ADJP (JJR Lower) (NN cost)) (NNS interventions)) (VP (VBG featuring) (NP (NP (NP (NN syringe) (NN access)) (PRN (-LRB- -LRB-) (NP (NNP SA)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (ADJP (RB medically) (VBN assisted)) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NNP MAT)) (-RRB- -RRB-))) (PP (IN for) (NP (NN addiction))))))) (VP (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB be) (ADJP (RBR less) (JJ costly))))))) (, ,) (CC but) (VP (VBP have) (VP (VBN shown) (NP (NP (JJ mixed) (NNS results)) (PP (IN in) (S (VP (VBG lowering) (NP (NNP HCV) (NNS rates)) (PP (IN below) (NP (JJ current) (NNS levels)))))))))) (. .))
(S (S (NP (NP (JJ Little))) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (JJ potential) (JJ synergistic) (NNS effects)) (PP (IN of) (S (VP (VBG combining) (NP (NNP DAA) (CC and) (NNP MAT) (NN treatment)))))))))) (, ,) (CC and) (S (NP (NP (JJ large-scale) (NNS tests)) (PP (IN of) (NP (JJ combined) (NNS interventions)))) (VP (VBP are) (ADJP (JJ rare)))) (. .))
(S (SBAR (IN While) (S (NP (NN simulation) (NNS experiments)) (VP (MD can) (VP (VB reveal) (NP (JJ likely) (JJ long-term) (NNS effects)))))) (, ,) (NP (JJS most) (JJ prior) (NNS simulations)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN on) (NP (NP (NP (JJ closed) (NNS populations)) (PP (IN of) (NP (NN model) (NNS agents)))) (: â€”) (NP (NP (DT a) (NN scenario)) (ADJP (RB quite) (JJ different) (PP (IN from) (NP (NP (DT the) (JJ open) (, ,) (JJ mobile) (NNS populations)) (VP (VBN known) (PP (TO to) (NP (RBS most) (NN health) (NNS agencies))))))))))))) (. .))
(S (NP (DT This) (NN paper)) (VP (VBZ uses) (NP (NP (NNS data)) (PP (IN from) (NP (NP (NP (NP (NP (DT the) (NNPS Centers)) (PP (IN for) (NP (NNP Disease) (NNP Control))) (POS 's)) (NNP National) (NNP HIV) (NNP Behavioral) (NNP Surveillance) (NN project)) (, ,) (NP (NNP IDU) (VBD round) (CD 3)) (, ,)) (VP (VBN collected) (PP (IN in) (NP (NNP New) (NNP York) (NNP City))) (PP (IN in) (NP (CD 2012))) (PP (IN by) (NP (NP (DT the) (NNP New) (NNP York) (NNP City) (NNP Department)) (PP (IN of) (NP (NP (NNP Health)) (CC and) (NP (NNP Mental) (NNP Hygiene)))))))))) (S (VP (TO to) (VP (VB parameterize) (NP (NP (NNS simulations)) (PP (IN of) (NP (JJ open) (NNS populations)))))))) (. .))
(S (NP (PRP$ Our) (NNS results)) (VP (VBP show) (SBAR (IN that) (, ,) (S (PP (IN in) (NP (DT an) (JJ open) (NN population))) (, ,) (NP (NP (NNP SA/MAT)) (PP (IN by) (NP (PRP itself)))) (VP (VBZ has) (NP (NP (RB only) (JJ small) (NNS effects)) (PP (IN on) (NP (NNP HCV) (NN prevalence)))) (, ,) (SBAR (IN while) (S (NP (NP (NNP DAA) (NN treatment)) (PP (IN by) (NP (PRP itself)))) (VP (MD can) (VP (ADVP (RB significantly)) (VB lower) (NP (DT both) (NP (NNP HCV)) (CC and) (NP (NNP HCV-related) (VBD advanced) (JJ liver) (NN disease) (NN prevalence))))))))))) (. .))
(S (ADVP (RBR More) (RB importantly)) (, ,) (X (NP (DT the) (NN simulation))) (VBZ experiments) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (ADJP (NN cost) (JJ effective)) (JJ synergistic) (NNS combinations)) (PP (IN of) (NP (DT the) (CD two) (NNS strategies)))) (VP (MD can) (VP (ADVP (RB dramatically)) (VB reduce) (NP (NNP HCV) (NN incidence))))))) (. .))
(S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (S (VP (VBG adopting) (NP (NNP SA/MAT) (NNS implementations)) (PP (RB alongside) (NP (NNP DAA) (NNS interventions))))) (VP (MD can) (VP (VB play) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (JJ long-term) (NNS consequences)) (PP (IN of) (NP (VBG ongoing) (NN infection)))))))))))) (. .))
